Characterization of Lipid Alterations by Oncogenic PIK3CA Mutations Using Untargeted Lipidomics in Breast Cancer

被引:2
|
作者
Jung, Jae Hun [1 ,2 ,3 ]
Yang, Da-Qing [1 ,4 ]
Song, Hongming [2 ]
Wang, Xiangyu [2 ]
Wu, Xinyan [1 ,2 ]
Kim, Kwang Pyo [3 ]
Pandey, Akhilesh [1 ,2 ,4 ,5 ,6 ]
Byeon, Seul Kee [1 ,2 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD USA
[3] Kyung Hee Univ, Dept Appl Chem, Yongin, South Korea
[4] Mayo Clin, Ctr Individualized Med, Rochester, MN USA
[5] Johns Hopkins Univ, Dept Biol Chem, Sch Med, Baltimore, MD USA
[6] Manipal Acad Higher Educ, Manipal, India
关键词
lipidomics; cancer; integrative biology; biomarkers; personalized medicine; mutations; P-31; NMR-SPECTROSCOPY; CELL-GROWTH; LYSOPHOSPHATIDYLCHOLINE; PLASMA; DROPLETS; LEUKEMIA; INVASION;
D O I
10.1089/omi.2023.0076
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Lipids play crucial biological roles in health and disease, including in cancers. The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a pivotal promoter of cell growth and proliferation in various types of cancer. The somatic mutations in PIK3CA, the gene coding for the catalytic subunit p110 & alpha; of PI3K, are frequently present in cancer cells, including breast cancer. Although the most prominent mutants, represented by single amino acid substitutions in the helical domain in exon 9 (E545K) and the kinase domain in exon 20 (H1047R) are known to cause a gain of PI3K function, activate AKT signaling and induce oncogenic transformation, the effect of these mutations on cellular lipid profiles has not been studied. We carried out untargeted lipidomics using liquid chromatography-tandem mass spectrometry to detect the lipid alterations in mammary gland epithelial MCF10A cells with isogenic knockin of these mutations. A total of 536 species of lipids were analyzed. We found that the levels of monosialogangliosides, signaling molecules known to enhance cell motility through PI3K/AKT pathway, were significantly higher in both mutants. In addition, triglycerides and ceramides, lipid molecules known to be involved in promoting lipid droplet production, cancer cell migration and invasion, were increased, whereas lysophosphatidylcholines and phosphatidylcholines that are known to inhibit cancer cell motility were decreased in both mutants. Our results provide novel insights into a potential link between altered lipid profile and carcinogenesis caused by the PIK3CA hotspot mutations. In addition, we suggest untargeted lipidomics offers prospects for precision/personalized medicine by unpacking new molecular substrates of cancer biology.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [31] Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
    Palimaru, Irina
    Brugmann, Anja
    Wium-Andersen, Marie Kim
    Nexo, Ebba
    Sorensen, Boe Sandahl
    SPRINGERPLUS, 2013, 2 : 1 - 7
  • [32] Prevalence and spectrum of PIK3CA mutations in Indian breast cancer patients
    Katara, Rahul
    Bhardwaj, Tina
    Rawat, Monika
    Sharma, Deepak K.
    Kumar, Vipin
    Sharma, Shivani
    Dagar, Vaishali
    Kumar, Pawan
    Mohanty, Sambit K.
    CANCER RESEARCH, 2024, 84 (06)
  • [33] The role of PIK3CA mutations in the development of breast cancer (a literature review)
    Pryvalova, A. O.
    Vynnychenko, I. O.
    Harbuzova, V. Yu
    Vynnychenko, O., I
    Moskalenko, Yu, V
    ZAPOROZHYE MEDICAL JOURNAL, 2020, 22 (04) : 554 - 560
  • [34] Assessment of clonal and subclonal PIK3CA mutations in patients with breast cancer
    Udhane, Sameer S.
    Alyaqoub, Fadel
    Noel, Pawan
    Kemkes, Ariane
    Flannery, Cynthia A.
    Innis, Paige E.
    Hall, David W.
    Thakkar, Snehal G.
    Basu, Gargi
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (03)
  • [35] PIK3CA mutations in breast cancer: A potential predictive marker.
    Santarpia, M.
    Altavilla, G.
    Margeli, M.
    Mesiti, M.
    Cavallari, V.
    Cirauqui, B.
    Reguart, N.
    Barnadas, A.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 37S - 37S
  • [36] Investigation of somatic PIK3CA gene mutations in breast cancer patients
    Pevzner, Alina M.
    Gaptulbarova, Ksenia A.
    Tsyganov, Matvey M.
    Ibragimova, Marina K.
    Vvedensky, Andrew V.
    Zhusina, Yulia G.
    Pyankov, Denis, V
    Korostylev, Sergey A.
    Litviakov, Nikolai, V
    JOURNAL OF BUON, 2021, 26 (03): : 747 - 752
  • [37] PIK3CA mutations in ovarian cancer -: Response
    Levine, DA
    Boyd, J
    CLINICAL CANCER RESEARCH, 2005, 11 (19) : 7042 - 7043
  • [38] The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients
    Tabesh, Ghasem Azizi
    Izadi, Pantea
    Fereidooni, Forouzandeh
    Razavi, Amir Nader Emami
    Bazzaz, Javad Tavakkoly
    CANCER INVESTIGATION, 2017, 35 (01) : 36 - 42
  • [39] AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
    Vasudevan, Krishna M.
    Barbie, David A.
    Davies, Michael A.
    Rabinovsky, Rosalia
    McNear, Chontelle J.
    Kim, Jessica J.
    Hennessy, Bryan T.
    Tseng, Hsiuyi
    Pochanard, Panisa
    Kim, So Young
    Dunn, Ian F.
    Schinzel, Anna C.
    Sandy, Peter
    Hoersch, Sebastian
    Sheng, Qing
    Gupta, Piyush B.
    Boehm, Jesse S.
    Reiling, Jan H.
    Silver, Serena
    Lu, Yiling
    Stemke-Hale, Katherine
    Dutta, Bhaskar
    Joy, Corwin
    Sahin, Aysegul A.
    Gonzalez-Angulo, Ana Maria
    Lluch, Ana
    Rameh, Lucia E.
    Jacks, Tyler
    Root, David E.
    Lander, Eric S.
    Mills, Gordon B.
    Hahn, William C.
    Sellers, William R.
    Garraway, Levi A.
    CANCER CELL, 2009, 16 (01) : 21 - 32
  • [40] Aspirin and PIK3CA Mutations in Colorectal Cancer
    Kirstein, M. M.
    Vogel, A.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (03): : 306 - 307